Zealand Pharma

Declaration of Voting Results & Voting Rights Announcements • Apr 30, 2015

Copenhagen, 2015-04-30 10:00 CEST (GLOBE NEWSWIRE) -- 30 April 2015 - Zealand
Pharma A/S (Nasdaq Copenhagen: ZEAL) (“Zealand”), in accordance with Section 6
of the Danish Statutory Order on Issuers' Disclosure Obligations, is required
to announce the total share capital and number of voting rights in the company
at the end of a month where changes therein have occurred.

With reference to Corporate Announcement no. 14/2015 dated 11 April 2015, the
table below provides the total number of shares and voting rights in Zealand as
of 30 April 2015.

         Number of shares  Nominal value  Number of votes
    (nominal value DKK 1)          (DKK)

---

Shares 23,420,100 23,420,100 23,420,100

                                  ?????

For further information, please contact:

Hanne Leth Hillman, Senior Vice President for Investor Relations &
Communications

Tel: +45 50 60 36 89, email: hlh@zealandpharma.com

About Zealand Pharma

Zealand Pharma A/S (“Zealand”) (Nasdaq Copenhagen: ZEAL) is a biotechnology
company based in Copenhagen, Denmark. Zealand has leading expertise in the
discovery, design and development of novel peptide medicines and possesses
in-house competences in clinical trial design and management with a therapeutic
focus on metabolic diseases and acute care indications. The company is
advancing a pipeline of novel wholly-owned medicines alongside a partnered
product and development portfolio.

Zealand’s first invented medicine, lixisenatide, a once-daily prandial GLP-1
agonist for the treatment of Type 2 diabetes, is marketed globally (ex-US) as
Lyxumia® and in Phase III development as a single-injection combination with
Lantus® (LixiLan), both under a global license agreement with Sanofi. US
regulatory submission of Lyxumia® is planned for Q3 2015 and US/EU regulatory
submissions for LixiLan in Q4 2015.

Zealand’s wholly-owned products include danegaptide (prevention of Ischemic
Reperfusion Injury) in Phase II and the stable glucagon product, ZP4207
(treatment of severe hypoglycemia) in Phase I as well as several preclinical
peptide therapeutics. Partnering represents an important component of strategy
to leverage in-house expertise, share development risk in large clinical
trials, provide funding and commercialize the company’s products. Zealand
currently has global license agreements and partnerships with Sanofi, Helsinn
Healthcare, Boehringer Ingelheim and Eli Lilly.

For further information: www.zealandpharma.com Follow us on Twitter
@ZealandPharma